In summary, our study demonstrates the feasibility and clinical value of the robust detection of the two most common BCL2 mutations underlying venetoclax resistance in a real-world cohort of patients with R/R CLL. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.